Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
ARL4AP1 is a pseudogene related to the ARF like GTPase 4A (ARL4A) gene. Pseudogenes are stretches of DNA resembling functional genes but generally lack the ability to code for active proteins. In some cases, pseudogenes can serve as regulators of other genes through RNA interference or microRNA decoy mechanisms, influencing expression of their corresponding coding genes. Currently, there is no direct evidence that ARL4AP1 has biological function or involvement in disease, nor is it considered a therapeutic target. Its parental gene, ARL4A, encodes a small GTP-binding protein involved in cellular signaling and is associated with non-syndromic X-linked intellectual disability, but these features do not extend to the pseudogene[1][2][5]. Key clarification: ARL4AP1 is not a receptor, enzyme, transporter, or any canonical therapeutic target. As a pseudogene, it does not produce a functional protein. The gene is correctly identified as a pseudogene rather than a genuine molecular target relevant for drug intervention, safety, or biomarker usage[2][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on ARF like GTPase 4A pseudogene 1 (ARL4AP1).